Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07739160 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 15, 2026 to Oct 2026 Show 4 more changesShow less
    • Primary completion date: Apr 30, 2027 to Apr 2027
    • Study completion date: Jul 31, 2027 to Jul 2027
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 2 of 5 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will evaluate the efficacy and safety of HRS-4029 compared with placebo in participants with acute ischemic stroke (AIS).
Trial Details
NCT Number NCT07739160
Lead Sponsor Beijing Suncadia Pharmaceuticals Co., Ltd
Conditions
(from sponsor)		 Acute Ischemic Stroke
Related terms Ischemic Stroke
Enrollment 340 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov